Clinical Trial: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223593) titled 'Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease' on Oct. 30.

Brief Summary: The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Peripheral Arterial Disease

Intervention: DRUG: Orforglipron

Administered orally

DRUG: Placebo

Administered orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lilly and Company

Published by HT Digital Content Services with permissio...